ABSTRACT:

Gastric cancer remains a significant health issue, particularly when occurring in younger populations with more aggressive forms and poorer outcomes. Here, we present the case of a 24-year-old female diagnosed with poorly differentiated gastric adenocarcinoma. She presented with severe epigastric pain, progressive dysphagia, hyper salivation, melena, and significant weight loss. Diagnostic evaluations revealed a subcardial mass suggestive of Bormann type III gastric cancer. Following a multidisciplinary decision, neoadjuvant chemotherapy with the FLOT regimen was initiated, resulting in a 10% reduction in tumor size. The patient underwent spleen-preserving total gastrectomy with Roux-en-Y reconstruction and extensive lymph node dissection. Postoperative pathology showed no residual neoplasm or lymph node metastasis. This case highlights the importance of a multimodal approach, demonstrating the efficacy of the FLOT regimen in achieving a complete pathological response and underscores the potential for favorable outcomes even in rare and aggressive cases of gastric cancer.

KEYWORDS:

Gastric Cancer, Young Adult, FLOT Regimen, Complete Pathological Response

REFERENCES :

1) W.-J. Yang et al., « Updates on global epidemiology, risk and prognostic factors of gastric cancer »,
2) World J. Gastroenterol., vol. 29, no 16, p. 2452‑2468, avr. 2023, 

doi: 10.3748/wjg.v29.i16.2452.
3) J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, et R. Sitarz, « Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies », Int. J. Mol. Sci., vol. 21, no 11, p. 4012, juin 2020, doi: 10.3390/ijms21114012.
4) F. M. Johnston et M. Beckman, « Updates on Management of Gastric Cancer », Curr. Oncol. Rep., vol. 21, no 8, p. 67, juin 2019, doi: 10.1007/s11912-019-0820-4.
5) A. Paszt et al., « Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy », Front. Surg., vol. 10, p. 1148984, 2023, doi: 10.3389/fsurg.2023.1148984.
6) L. H. Schwartz et al., « RECIST 1.1 – Update and Clarification: From the RECIST Committee », Eur. J. Cancer Oxf. Engl. 1990, vol. 62, p. 132‑137, juill. 2016, doi: 10.1016/j.ejca.2016.03.081.
7) B. De et al., « Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States », Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc., vol. 21, no 6, p. 889‑899, nov. 2018, doi: 10.1007/s10120-018-0826-x.
8) A. W. Smith et al., « Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study », J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 31, no 17, p. 2136‑2145, juin 2013, doi: 10.1200/JCO.2012.47.3173.
9) K. A. Rona et al., « Gastric cancer in the young: An advanced disease with poor prognostic features », J. Surg. Oncol., vol. 115, no 4, p. 371‑375, mars 2017, doi: 10.1002/jso.24533.
10) M. C. V. Cormedi, M. L. H. Katayama, R. S. C. Guindalini, S. F. Faraj, et M. A. A. K. Folgueira,
11) « Survival and prognosis of young adults with gastric cancer », Clin. Sao Paulo Braz., vol. 73, no suppl 1, p. e651s, sept. 2018, doi: 10.6061/clinics/2018/e651s.
12) Y. Kono, H. Kanzaki, M. Iwamuro, S. Kawano, Y. Kawahara, et H. Okada, « Reality of Gastric Cancer in Young Patients: The Importance and Difficulty of the Early Diagnosis, Prevention and
13) Treatment », Acta Med. Okayama, vol. 74, no 6, p. 461‑466, déc. 2020, doi: 10.18926/AMO/61204.
14) A. Adenis, E. Samalin, T. Mazard, F. Portales, A. Mourregot, et M. Ychou, « Le protocole FLOT est-il le nouveau standard de chimiothérapie péri-opératoire des cancers de l’estomac ? », Bull. Cancer (Paris), vol. 107, no 1, p. 54‑60, janv. 2020, 

doi: 10.1016/j.bulcan.2019.12.005.
15) S.-E. Al-Batran et al., « Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. », J. Clin. Oncol., vol. 35, no 15_suppl, p. 4004‑4004, mai 2017, doi: 10.1200/JCO.2017.35.15_suppl.4004.
16) A. D. Wagner et al., « Chemotherapy for advanced gastric cancer », Cochrane Database Syst. Rev., vol. 8, no 8, p. CD004064, août 2017, doi: 10.1002/14651858.CD004064.pub4.
17) S.-E. Al-Batran et al., « Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial », The Lancet, vol. 393, no 10184, p. 1948‑1957, mai 2019, doi: 10.1016/S0140- 6736(18)32557-1.
18) Z. Li et al., « Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta- analysis », PloS One, vol. 13, no 1, p. e0189294, 2018, doi: 10.1371/journal.pone.0189294.
19) C. Kaltenmeier et al., « Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes », Am. Surg., vol. 87, no 7, p. 1145‑1154, juill. 2021, doi: 10.1177/0003134820972083.
20) T. Wang, C. Li, X. Li, J. Zhai, S. Wang, et L. Shen, « The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis », Eur. J. Med. Res., vol. 27, no 1, p. 239, nov. 2022, doi: 10.1186/s40001-022-00878-7.
21) K. Tada et al., « A case of advanced gastric cancer achieved a pathological complete response by chemotherapy », Surg. Case Rep., vol. 3, no 1, p. 68, mai 2017, 

doi: 10.1186/s40792-017-0344-9.
22) S. Endo et al., « Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report », Surg. Case Rep., vol. 6, no 1, p. 276, oct. 2020, doi: 10.1186/s40792- 020-01053-y.
23) C. Zhang et al., « Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score
24) matching », World J. Surg. Oncol., vol. 21, no 1, p. 350, nov. 2023, 

doi: 10.1186/s12957-023-03221- 4.
25) T. Yoshikawa et al., « Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer », Br. J. Surg., vol. 96, no 9, p. 1015‑1022, sept. 2009, doi: 10.1002/bjs.6665.
26) K. Fujitani et al., « Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction », Ann. Surg. Oncol., vol. 14, no 7, p. 2010‑2017, juill. 2007, doi: 10.1245/s10434-006-9198-2.
27) Q. Ling et al., « Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis », World J. Surg. Oncol., vol. 21, no 1, p. 377, déc. 2023, doi: 10.1186/s12957-023-03251-y.
28) M. Ychou et al., « Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial », J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 29, no 13, p. 1715‑1721, mai 2011, doi: 10.1200/JCO.2010.33.0597.
29) T. Wang et al., « Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection », Transl. Cancer Res., vol. 9, no 2, p. 529‑535, févr. 2020, doi: 10.21037/tcr.2019.11.37.
30) H. Cho et al., « Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature », Ann. Surg. Oncol., vol. 22, no 3, p. 787‑792, mars 2015, doi: 10.1245/s10434-014-4084- 9.
31) J. C. Mansour et al., « Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? », Ann. Surg. Oncol.,  vol. 14, no 12, p. 3412‑3418, déc. 2007, doi: 10.1245/s10434-007-9574-